Background: Tazemetostat (EPZ-6438) is a selective inhibitor of the histone methyltransferase EZH2 and currently in clinical development for non-Hodgkin lymphoma and genetically defined tumors.
INTRODUCTION
Enhancer of zeste homolog 2 (EZH2) is the functional enzymatic component of the multiprotein histone methyltransferase complex known Abbreviations: C max , maximum plasma concentration; EFS T/C, ratio of event-free survival treated/control; EPZ-6438, tazemetostat; EZH2, enhancer of zeste homolog 2; FL, follicular lymphoma; H3K27me3, histone H3 lysine 27 trimethylation; MRT/ATRT, malignant rhabdoid tumor/atupical teratoid-rhabdoid tumor; (NOD)/scid −/− , nonobese diabetic/severe combined immune deficient; PPTP, Pediatric Preclinical Testing Program; SCCOHT, small cell cancer of the ovary of the hypercalcemic type; SD, stable disease as polycomb repressive complex 2 (PRC2) and is responsible for the H3K27 trimethylation activity of the complex. 1 An oncogenic role for EZH2 has been demonstrated for several cancer types. 2 For example, heterozygous EZH2 mutations within the catalytic SET domain have been observed in approximately 20% of cases of germinal center B-cell (GCB)-like diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). [3] [4] [5] [6] [7] These activating mutations in EZH2 result in massive increases in H3K27 trimethylation, leading to abnormal repression of PRC2 targets and lymphoma development. 8, 9 These findings provided the basis for EZH2 inhibition as a specific rational therapy for germinal center-derived B-cell Non-Hodgkins lymphoma (NHL).
Regulation of stem cell differentiation by polycomb group proteins is mediated via repression of gene transcription. 10 In differentiated myogenic tissues, EZH2 is either very low or not detectable. 11 For RD embryonal rhabdomyosarcoma cells, forced expression of EZH2 inhibited differentiation, whereas genetic or pharmacologic inhibition of EZH2 induced differentiation. 11 In PAX3-FOXO1 expressing alveolar rhabdomyosarcoma cells, suppression of EZH2 led to apoptosis. 12 Indirect inhibition of EZH2 by 3-deazaneplanocin A (an inhibitor of Sadenosylhomocysteine hydrolase) and inhibition by an EZH2 catalytic inhibitor slowed tumor growth for an alveolar rhabdomyosarcoma xenograft. 12 Multiple cell lines and animal models have demonstrated sensitivity to EZH2 inhibition, including tumor models of diffuse large B-cell lymphoma, 13, 14 rhabdoid tumor, 15 mesothelioma, 16 and ependymoma. 17 It has been proposed that tumors such as malignant rhabdoid tumors (MRTs) and atypical teratoid rhabdoid tumors (ATRTs) that are deficient in the SWI/SNF complex by virtue of SMARCB1 (also known as INI1) deletion have a synthetic lethal dependency on EZH2. 18 Tazemetostat is one of several potent and selective small molecule EZH2 inhibitors that have been recently reported. [13] [14] [15] 19, 20 These inhibitors compete with the methyl group donor S-adenosyl methionine to suppress the enzymatic activity of EZH2. Tazemetostat inhibits wild-type and mutant EZH2 and is highly selective against EZH2 over other histone methyltransferases. Tazemetostat is among the most potent EZH2 inhibitors described to date and demonstrates superior pharmacokinetic properties, including good oral bioavailability in animals. 14, 21 Tazemetostat showed impressive in vitro and in vivo activity against a rhabdoid tumor model (G401). 21 It is currently under clinical investigation for diffuse large cell B-lymphoma and FL as well as SMARCB1-deficient and SMARCA4-deficient solid tumors. Here we report the antitumor activity of tazemetostat against seven panels of pediatric solid tumor xenograft models including an expanded panel of MRT/ATRT.
MATERIALS AND METHODS

In vivo tumor growth inhibition studies
CB17SC scid −/− female mice (Taconic Farms, Germantown, New York) were used to propagate subcutaneously implanted kidney/rhabdoid tumors, sarcomas (Ewing, osteosarcoma, rhabdomyosarcoma), neuroblastoma, and brain tumors. Female mice were used irrespective of the patient gender from which the original tumor was derived. All mice were maintained under barrier conditions and experiments were conducted using protocols and conditions approved by the institutional animal care and use committee at the Research Institute, Nationwide Children's Hospital. Ten mice were used in each control or treatment group. Tumor volumes (cm 3 ) were determined and responses were calculated using three activity measures as previously described. 22 An indepth description of the analysis methods is included in Supplementary Appendix S1 (Response Definitions section).
Statistical methods
The exact log-rank test, as implemented using Proc StatXact for SAS R , was used to compare event-free survival (EFS) distributions between treatment and control groups. P values were two-sided and not adjusted for multiple comparisons given the exploratory nature of the studies. 
Drugs and formulation
Pharmacodynamic studies
Tumors were harvested during treatment when they evented and 100 l per well BioFx Supersensitive TMB substrate was added.
Samples were developed for 5 min at room temperature. The reaction was terminated (100 l per well 1N H 2 SO 4 ) and absorbance was read at 450 nm (Envision plate reader).
Expression analysis
Agilent Sureprint 3 data was collected, the foreground signal of each feature was extracted and the effect of hybridization differences was 
RESULTS
Tazemetostat was tested against the PPTP panels of solid tumor xenografts using a dose of 400 mg/kg (350 mg/kg active drug) administered twice daily by oral gavage for 28 days. The total planned treatment and observation period was 6 weeks. Tazemetostat was generally well tolerated, with a 3.1% (nine of 291) mortality rate in the treated groups, which is a nonsignificant increase compared with control animals (three of 286; 1%). Complete details of testing are elucidated in Supplementary Table S1 , including total numbers of mice, number of mice that died (or were otherwise excluded), numbers of mice with tumor events and average times to event, and tumor growth delay, as well as numbers of responses and T/C values.
Thirty of 30 tested xenograft models were considered evaluable for efficacy. Tazemetostat induced significant differences in EFS distribution compared with control in nine of 30 (30%) of the evaluable xenografts studied (Table 1) Supplementary Fig. S1 ), including four models tested here, is undetectable.
For the objective response metric, one MRT xenograft (G401)
showed stable disease (SD). Progressive disease 2 (PD2) response, defined by progressive disease with growth delay (EFS T/C >1.5), was observed in additional three MRT xenografts (Fig. 1) . Tazeme a EFS T/C value is defined by the ratio of the median time to event of the treatment group and the median time to event of the respective control group. High activity requires the following: (i) an EFS T/C > 2; (ii) a significant difference in EFS distributions; and (iii) a net reduction in median tumor volume for animals in the treated group at the end of treatment as compared to at-treatment initiation. Intermediate activity demonstrates criteria (i) and (ii) above, but not having a net reduction in median tumor volume for treated animals at the end of the study. Low activity demonstrates EFS T/C < 2. To determine pharmacodynamic effects of tazemetostat, tumors were harvested at time of event on treatment, or at various time periods after completion of treatment when tumor-bearing mice completed the 28-day course of treatment. Histones were extracted using the procedures of Daigle et al. 23 and assayed for total histone H3 and H3K27me3 using an ELISA as described by Knutson et al. 14 (Fig. 4B) . The Ewing sarcoma CHLA-258 not only exhibited high H3K27me3 levels but also had high EZH2 expression at the mRNA level (Fig. 4B ).
DISCUSSION
Mono-, di-, and tri-methylation at the H3K27 site is uniquely mediated by PRC2, being specified by the EZH2 SET domain. 24 Mice lacking Ezh2 are not viable and show severe developmental and proliferative defects. 25 Through H3K27me3, EZH2 suppresses differentiation of mesenchymal stem cells and potential cancer stem cells. 26 Point mutations that increase the catalytic activity of EZH2 promote cell transformation in subsets of B-cell neoplasms, thus making EZH2 a compelling target in this genetically defined patient population. 27 EZH2 inhibitors were shown to have strong antitumor effects against human B-cell lymphoma xenograft models. 14, 20 MRTs and ATRTs are extremely aggressive pediatric cancers that are characterized by the homozygous loss of SMARCB1, a core component of the SWI/SNF chromatin remodeling complex. 28 Reciprocal expression has been reported between EZH2 and SMARCB1, and EZH2 has been shown to be required for the development of SMARCB1-deficient tumors such as MRTs and ATRTs. 18, 28, 29 Tazemetostat showed in vitro and in vivo activity against a SMARCB1-mutant MRT model. 21 
SMARCA4-deleted
ovarian cancer, such as small cell cancer of the ovary of the hypercalcemic type (SCCOHT), has also been shown to be responsive to EZH2 inhibition. 30 Clinical trials are underway to evaluate tazemetostat against these SWI/SNF mutant cancers.
We tested 30 xenograft models from the PPTP solid tumor panels. Tazemetostat (Fig. 1) . This is in agreement with previously reported results for the G401 xenograft in which tumor regression was observed with a delay of 5-7 days after starting treatment. 21 Tumor re-growth after cessation of dosing was observed in all three EZH2 inhibitors has been suggested to be caused by increased expression of ABCB1 and ABCG2 drug transporters. 34 Tazemetostat is a substrate for ABCB1 (P-glycoprotein)-mediated efflux, and we noted that the expression of this pump is greater than the panel mean level in two xenografts (NB-EBc1 and NB-1691 xenografts; data not shown).
However, H3K27me3 levels were reduced to a similar level in the NB-EBc1 xenograft as other xenograft models, suggesting that this xenograft model is not preventing tazemetostat target engagement, but rather it is not sensitive to EZH2 inhibition.
Clinical results for tazemetostat support the importance of loss of SWI/SNF function as one predictor for sensitivity to the agent. 35 F I G U R E 3 (A) The heat map depicting group response scores. A high level of activity with tumor regression is indicated by a "Median Score" of 6 or more, intermediate activity by a score of 2 or more but less than 6, and low activity by a score of less than 2. The "Median Score" ranges from 0 for PD1 responses to 10 for MCR objective responses, with the "Midpoint Difference" reflecting the difference between the Median Score and the Midpoint Response (5 for SD). The log-rank P value is for the difference in EFS distribution for treated and control groups. (B) Representation of tumor sensitivity based on the difference of individual tumor lines from the midpoint response (SD). Bars to the right of the median represent tumor regression and those to the left are tumor models that progress. Red bars indicate xenograft models with a significant difference in EFS distribution between treatment and control groups, while blue bars indicate lines for which the EFS distributions were not significantly different
In a phase 1 trial for adults with cancer, dose levels from 100 to 1600 mg twice daily were evaluated with expansion cohorts at 800 and 1,600 mg twice daily. 35 In summary, pediatric preclinical testing of tazemetostat, a novel, potent, and selective EZH2 inhibitor, demonstrated significant antitumor activity in rhabdoid tumor xenograft models; however, limited activity was found in the panel of solid tumors studied as a whole.
The phenomenon of delayed tumor response should be further investigated and may need to be considered when developing clinical trials for this class of agents. Our results suggest that there is heterogeneity in response to EZH2 inhibitors and that the heterogeneity in response is unlikely to be the result of differential reduction in H3K27me3.
These results additionally provide impetus for further studying this heterogeneity. The data also provide a cautionary note against expectations for uniform high-level clinical activity for EZH2 inhibitors against rhabdoid tumors. with glucocorticoid receptor agonists in models of germinal center non-Hodgkin lymphoma, and enhance doxorubicin and paclitaxel activity. 40, 41 Further evaluation of tazemetostat in preclinical models with mutations considered to predispose to drug sensitivity (e.g.,
SMARCB1
, SMARCA4) in combination with conventional chemotherapeutics agents may be a valuable approach to develop for this class of epigenetic modifier.
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